Summary of significant correlations between the clinical features and recurring breakpoints
| Clinical feature . | Recurring site . | Present (%) . | Absent (%) . | P . |
|---|---|---|---|---|
| Female | 7q11 | 06/06 (100) | 19/40 (47) | .025 |
| Male | 3p21 | 05/05 (100) | 14/41 (34) | .008 |
| Stage III-IV | 3q27 | 11/13 (85) | 15/32 (47) | .024 |
| High or high-intermediate risk | 2q31 | 06/06 (100) | 23/36 (63) | .016 |
| 3q27 | 13/13 (100) | 17/30 (57) | .004 | |
| Poor response to treatment | 2q31 | 04/07 (57) | 06/36 (18) | .040 |
| 7q22 | 03/05 (60) | 07/38 (18) | .033 |
| Clinical feature . | Recurring site . | Present (%) . | Absent (%) . | P . |
|---|---|---|---|---|
| Female | 7q11 | 06/06 (100) | 19/40 (47) | .025 |
| Male | 3p21 | 05/05 (100) | 14/41 (34) | .008 |
| Stage III-IV | 3q27 | 11/13 (85) | 15/32 (47) | .024 |
| High or high-intermediate risk | 2q31 | 06/06 (100) | 23/36 (63) | .016 |
| 3q27 | 13/13 (100) | 17/30 (57) | .004 | |
| Poor response to treatment | 2q31 | 04/07 (57) | 06/36 (18) | .040 |
| 7q22 | 03/05 (60) | 07/38 (18) | .033 |